CGTuniQure sells royalty interest in gene therapy for $400muniQure N.V. is to sell a portion of its royalty rights from the net sales o its hemophilia B gene therapy etranacogene dezaparvovec-drbl to HealthCare Royalty and Sagard Healthcare for a gross purchase … more ➔
financingDualyx NV raises €40m in Series A financing Belgian T reg specialist Dualyx NV had raised €40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic. more ➔
RSVSanofi’s/Astazeneca’s anti-RSV antibody highly effectiveNHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial. more ➔
partnershipMainz Biomed Partners with Microba Life SciencesMolecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc. more ➔
financingDiogenX SA raises €27.5M in Series A financing French pancreatic beta-cell modulator specialist DiogenX SA has raised €27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund. more ➔
M&AWacker AG expands biotech business through €100m acquisitionMunich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for €100m. more ➔
partnershipNeogap Therapeutics AB partners with Cellerys AGSwedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial. more ➔
CDMODutch State to sell share capital of Intravacc BVThe State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V. more ➔
partnershipTay Therapeutics in licensing deal with VYNE TherapeuticsTay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders. more ➔
Medigene licences CD40L-CD28 costimulatory switch receptorGerman Medigene AG has acquired global rights to the CD40L-CD28 costimulatory switch receptor that modulates the tumour stroma in order to make T-TCR therapies more effective. more ➔
